Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | WNT3A | P56704 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491513 | 0.78 | EGFR (0.45) | — | |
| SCHEMBL8536931 | 0.73 | HCAR2 (0.33) | NPC1SMN1; SMN2WNT3ARAB9A | |
| SCHEMBL9346948 | 0.73 | SMN1; SMN2 (0.41) | NPC1GAASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL5182822 | 0.72 | GAA (0.69) | NPC1GAASMN1; SMN2ALDH1A1CHRNB2 | |
| SCHEMBL11296558 | 0.72 | L3MBTL1 (0.44) | NPC1GAASMN1; SMN2GLSRAB9A | |
| SCHEMBL513745 | 0.72 | NR3C2 (0.38) | NPC1GAAALDH1A1 | |
| SCHEMBL88751 | 0.70 | ALDH1A1 (0.39) | NPC1GAASMN1; SMN2GSK3BALDH1A1 | |
| SCHEMBL9790163 | 0.69 | RAB9A (0.36) | NPC1SMN1; SMN2RAB9A | |
| SCHEMBL3368295 | 0.69 | KDM4E (0.44) | NPC1GAASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL18618752 | 0.69 | NPC1 (0.36) | NPC1GAASMN1; SMN2ALDH1A1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507818-B2 | Method for the production of alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2009-03-24 | — | — | US | disclosed |
| US-7371856-B2 | Preparation of alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20070083047-A1 | Preparation of Alkoxycarbonylaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-12 | — | — | US | disclosed |
| US-7169923-B2 | Method for preparing alkoxycarbonylamino-triazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20060069254-A1 | Method for the production of alkoxycarbonylamino triazines | BASF AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | US | disclosed |
| US-20040249149-A1 | Method for preparing alkoxycarbonylamino-triazines | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249149-A1 | Method for preparing alkoxycarbonylamino-triazines | ADH1C, PNMT, TET2 | NPC1 4123/4885GAA 2099/4885NQO2 1630/4885 |
| US-20060069254-A1 | Method for the production of alkoxycarbonylamino triazines | ADH1C, ADH5, ADH1A | NPC1 3027/4885GAA 1219/4885NQO2 576/4885 |
| US-20070083047-A1 | Preparation of Alkoxycarbonylaminotriazines | ADH1C, TET2, PNMT | NPC1 4355/4885GAA 1542/4885NQO2 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.